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It has been known that the RSV fusion protein F is a target vaccine protein to produce a protective immune 
response. The VRC has shown (Ngwuta, et.al.) through binding competition assays that the amount of pre-
fusion site Ø–specific antibodies correlates with neutralizing (NT) activity, whereas the pre/post-fusion site II 
mAbs does not correlate with neutralization. Our results indicate that RSV NT activity in human sera is primarily 
derived from pre-F–specific antibodies, and therefore, inducing or boosting NT activity by vaccination will be 
facilitated by using pre-F antigens that preserve site Ø.  Therefore, the instability of the RSV pre-fusion 
conformation has limited the potential of this as a vaccine antigen.  Therefore, the VRC has designed a 
structurally stabilized glycoprotein pre-fusion RSV F trimer vaccine antigen and has shown it to be highly 
immunogenic in preclinical studies.  A description of challenges in the development of a high productivity CHO 
cell line, production process and product quality and antigenic characterization assays for Phase I clinical 





Figure 1.  Antigenic Site Ø on pre-fusion and post-fusion RSV-F.  Trimer on the left and monomer on the 
right. (McLellan et al. Science 2013). 
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